Effect of Probiotics or Berberine in Hepatic Steatosis Markers, Cardiometabolic and Microbiotic Profile in NAFL.

  • STATUS
    Recruiting
  • End date
    Jun 1, 2024
  • participants needed
    140
  • sponsor
    Poznan University of Medical Sciences
Send
Updated on 7 October 2022
See if I qualify
diabetes
body mass index
fatty liver

Summary

Effect of oral selected Probiotics (PRO) and/or Berberine (BBR) supplementation on hepatic steatosis markers, cardiometabolic profile, and gut microbiota profile in the non-alcoholic fatty liver (NAFL) - a randomized double-blind clinical study.

Description

Probiotics (PRO) and bioactive natural substances such as Berberine (BBR) can improve metabolic parameters in patients with obesity and metabolic disorders. In addition, they significantly affect the composition and function of gut microbiota (GM) and support anti-inflammation and antioxidant defense. These data have become the starting point for the proposed multidirectional approach, aimed at assessing the effect of PRO and/or BBR supplementation on:

  • hepatic-related outcomes,
  • changes in anthropometric measurements (body mass, BMI, body mass composition and fat mass % content),
  • cardiometabolic profile (e.g. blood pressure, noninvasive markers of endothelial function, cardiometabolic biochemical parameters)
  • microbiotic profile (gut microbiota composition, endotoxemia)
  • the content of the minerals, in overweight/obese patients with nonalcoholic fatty liver (NAFL).

Details
Condition Non Alcoholic Fatty Liver, Obesity
Treatment Placebo, Berberine, Probiotic, Probiotc and Berberine
Clinical Study IdentifierNCT05523024
SponsorPoznan University of Medical Sciences
Last Modified on7 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

age 40 to 60 years
women ≥1 year since last menstruation
body mass index (BMI): 27.0 kg/m2 to 34.9 kg/m2
abdominal obesity-related waist circumference > 80 cm (women) and >94 cm (men) (in accordance to International Diabetes Federation)
stable body weight in the 3 months prior to the trial (permissible deviation is ± 3 kg)
NAFL - diagnosed based on USG in accordance with PGE-NAFLD recommendation

Exclusion Criteria

history of following alternative diets within 3 months before the study
history of use of any dietary supplements in the 3 months before the study
history of intake of antibiotics, probiotics, prebiotics within 3 months before the study
secondary form of obesity, pharmacological treatment for obesity (in the 3 months before the study), history of bariatric surgery
another liver diseases: high risk of NASH (assessed on the FIB-4, according to the PGE-NAFLD recommendation), autoimmune hepatitis, hepatitis B and C, toxic hepatitis, cirrhosis, Wilson's disease, hemochromatosis
other gastrointestinal disorders, especially: IBD, celiac disease, gastritis and duodenitis, pancreatic disorders, gastrointestinal symptoms suggestive of IBS
clinically significant acute inflammatory process (elevated hsCRP)
abnormal kidney function (GFR <60mL/min/1,73m2)
T2D
dyslipidemia or hypertension - requiring the introduction and/or change of pharmacological treatment in the 6 months before the trial or during intervention
pump inhibitors, anticoagulants, drugs causing metabolic alteration, e.g., SFAs (second-generation antipsychotics)
diseases requiring nutritional requirement and chronic supplementation
alcohol (>30g/d for men and >20g/d for women), nicotine or drug abuse
mental disorders, including eating disorders
cancer, autoimmune diseases
any other condition which may influence on final results of the study or pose a risk for subjects health
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

diabetes
body mass index
fatty liver

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note